PDCD1 and endometrial cancer: Similarly, the pooled HR for OS in patients with endometrial cancer who received PD-1 inhibitors was 0.62 (95% CI: 0.54-0.72, p <.001; I2 = 0%, Cochran’s p =.16) (Supplementary Figure 2A) (23–25).